This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Link between effectiveness and cost data
The costing was carried out prospectively on the same patient sample as that used in the effectiveness analysis.
Study sample
Primary power calculations were performed in the preliminary phase of the study. These indicated that the sample size should be 100 patients in each study group, on the basis of an alpha-value of 0.05 and a power of 80% for an alternative hypothesis of a 35% relative reduction in the primary outcome measure. The study included English-speaking eligible patients admitted at the study hospitals between December 1996 and December 1998. A total of 1,252 patients were found to be ineligible, mainly due to lack of high-risk condition or NYHA functional class III/IV CHF. In particular, 11.9% of the patients refused to participate and 2.3% were excluded because their primary physicians declined to participate. A sample of 200 patients was enrolled in the study. There were 102 individuals in the intervention group and 98 in the control group. The mean age in the intervention group was 60.2 (+/-13.8) years (range: 25 -87), 64.7% were men, and 63.7% were white. The mean age in the control group was 63.7 (+/-15) years (range: 26 -88), 56.1% were men, and 64.3% were white. No patient was excluded from the initial sample. It should be noted that after inclusion in the study, patients in the final sample were no longer in NYHA functional class III/IV.
Study design
This was a prospective, randomised controlled trial, carried out in two centres, the Johns Hopkins Hospital and the Johns Hopkins Bayview Medical Center in Baltimore. The randomisation was performed by a coordinating centre using an automated telephone response system and random number schedules. The randomisation was stratified by site and by the presence of left ventricular systolic dysfunction, such as LVEF less than 45%. The patients were followed for 6 months and were assessed at baseline and at the end of the study. No patients were lost to follow-up. Assessors in the coordinating centre were blinded to the treatment assignment.
Analysis of effectiveness
The basis for the analysis of the clinical study was intention to treat. The primary health outcome was the composite of death from any causes and the total number of CHF hospital admissions. The secondary health outcomes were patientassessed CHF symptoms, presence of ankle oedema, reaching goal weight, diet compliance, use of medications, qualityof-life scores and activity status. Quality-of-life scores were measured using the Minnesota Living with Heart Failure Questionnaire, which ranged from zero (best score) to 105 (worst score). The activity status was assessed using the Duke Activity Status Index, which ranged from 12 (best score) to zero (worst score). The study groups were shown to be comparable at baseline.
Effectiveness results
There were 7 deaths (6.9%) in the intervention group and 13 deaths (13.4%) in the control group.
There were 43 hospital admissions for CHF among 26 patients in the intervention group, and 59 hospital admissions for CHF among 35 patients in the control group. These differences did not reach statistical significance.
For the secondary outcomes, only the following differences reached statistical significance: 12% of patients in the intervention group reported a worsening of their symptoms, compared with 35% in the control group;
the presence of ankle oedema was 20% in the intervention group and 41% in the control group;
50% of the patients in the intervention group reached their goal weight, compared with 20% of those in the control group;
diet compliance was poor in 27% of the patients in the intervention group and 52% of those in the control group; the mean change from baseline was -28.3 (median -28) in the intervention group and -15.7 (median -15) in the control group;
in terms of the Duke activity status, the mean value of the total score at the final visit was 6.8 (median 6; 25th and 75th percentile: 5 -9) in the intervention group and 6.0 (median 6; 25th and 75th percentile: 4 -8) in the control group, (p=0.5).
No difference was found in the mean change from baseline.
The authors also stated that statistical analyses showed that only diabetes and an ischaemic cause of CHF independently predicted readmissions for CHF or death.
Clinical conclusions
The effectiveness analysis showed that, compared with the non intervention group, there were statistically significant improvements in quality-of-life scores and diet compliance in the intervention group. There was also a non statistically significant trend towards a benefit in terms of a reduction in deaths and hospital admissions in the intervention group.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used. A cost-consequences analysis was therefore conducted.
Direct costs
Discounting was not performed, or necessary, as the time horizon of the study was 6 months. The unit costs and quantities of resources were not reported. The health services included in the cost analysis were personnel, supplies, outpatient pharmacy and hospital stay. The cost/resource boundary adopted in the analysis appears to have been that of the hospital. The wages were derived from published studies and reflected the actual time spent with patients. The pharmacy costs were derived from actual wholesale prices. The supplies included medications, diet programme, transportation to the clinic, pill sorters and telephones. The inpatient costs were obtained by applying state-regulatory cost-to-charge ratios and annual inflation factors to actual charges. The quantities of resources used were derived from the trial and were collected between December 1996 and December 1998. The price year was 1998.
